LONDON -- The FTSE 100 (FTSEINDICES: ^FTSE ) perked up a bit yesterday to end the day on 6,558 points, but it has turned tail again today to fall 95 points, or 1.44%, to 6,464 by 9:30 a.m. EDT. Despite the apparent lessening of fears concerning the possible end of economic stimulus measures, a weak session in Asian markets led to a bearish opening in London. Until we get concrete updates on American and European monetary policies, the market looks likely to continue in this uncertain manner.
So which companies are leading the FTSE down? Here are three names that are slipping and look set to lag the index today.
Tesco
Tesco shares have fallen 4.6% after the U.K.'s biggest supermarket chain revealed a fall in like-for-like sales in its first-quarter update.�In the U.K., we saw a 1% fall, but in other markets things were worse, down 3.8% in Asia and down a scary 5.5% in Europe (all excluding petrol sales). Total group sales were actually up 2.7%, but in like-for-like terms that translated to a fall of 2.2%.
5 Best Forestry Stocks To Invest In 2015: CareFusion Corp (CFN)
CareFusion Corporation (CareFusion), incorporated on January 14, 2009, is a global medical technology company. The Company operates in two segments: Medical Systems and Procedural Solutions. The Medical Systems segment is organized around its medical equipment businesses. The Company�� Medical Systems segment�� business units and product lines include Infusion Systems, Dispensing Technologies, and Respiratory Technologies. The Procedural Solutions segment is organized around the Company�� disposable products and reusable surgical instruments businesses. The Company�� Procedural Solutions segment�� business units and product lines include Infection Prevention, Medical Specialties and Specialty Disposables. In August 2011, the Company acquired Rowa. In June 2012, the Company acquired U.K. Medical Limited. In July 2012, Natus Medical, Inc. acquired the Nicolet neurodiagnostic business from CareFusion. Effective December 31, 2013, CareFusion Corp acquired Vital Signs Inc from GE Healthcare, a unit of General Electric Co.
Medical Systems Segment
The Company�� develops, manufactures and markets capital equipment and related supplies for medication management, which includes its infusion and medication dispensing technologies, supply dispensing technologies and respiratory technologies. Its products are designed to enable healthcare professionals to improve patient safety by reducing medication errors and improving administrative controls, while simultaneously improving workflow and increasing operational efficiency. The Company sells these products primarily through its direct sales force, but use third-party distributors as well, particularly outside the United States. Many of its products in this segment are integrated with other information systems within the hospital, including financial and business systems that support patient admissions, discharges and transfers, operational systems that include inventory management and clinical systems that include pharmacy inf! ormation and electronic medical records.
The Company offers value-added services and programs, software technical services and clinical education, which are designed to enhance its customers��utilization of its medical equipment products. The Company�� project management, field service organization and customer call centers support its customers before, during and after product installation. The Company�� project management teams assist customers with the development of project implementation plans, which are designed to ensure rapid, seamless implementation of its products. The Company�� field service organization provides on-site expertise to resolve customers��service issues. The Company�� customer call centers provide additional support to its customers.
The Company is engaged in designing, developing and marketing of IV infusion systems that deliver medications and other fluids directly into a patient�� veins in precise, measured quantities over a range of infusion rates. The Company is provider of point-of-care systems that automate the dispensing of medications and supplies in hospitals and other healthcare facilities in the United States. The Company develops, manufactures, markets and services mechanical ventilators and associated consumables for patients with respiratory disorders.
The Company competes with Baxter International, B. Braun, Fresenius Kabi, Hospira, Omnicell, McKesson; Drager, and MAQUET.
Procedural Solutions Segment
The Procedural Solutions segment is organized around its disposable products and reusable surgical instruments businesses. In its Procedural Solutions segment, the Company develops, manufactures and markets single-use skin antiseptic and other patient-preparation products, non-dedicated IV infusion administration sets and accessories, reusable surgical instruments and non-dedicated ventilator circuits and other disposables used for providing respiratory therapy. The products in this segm! ent are u! sed in the operating room, interventional suites, and in the critical care departments of hospitals. The Company sells these products and services through a combination of direct sales representatives and third-party distributors.
The Company�� Infection Prevention business unit consists mainly of single-use medical products used in surgical and vascular access procedures, including skin preparation products and disposable IV infusion administration sets and accessories. The Company�� Medical Specialties business unit consists mainly of specialty medical devices used in delivering interventional care and reusable surgical instrumentation products. The Company�� Specialty Disposables business unit focuses on providing clinicians with respiratory consumable products that work either independently or in conjunction with its range of ventilators.
The Company competes with 3M, ICU Medical, Becton, Dickinson, Baxter International, B. Braun; Hospira; Smiths Medical; CR Bard, Integra Life Sciences, and Teleflex.
Advisors' Opinion:- [By John Udovich]
Overlooked mid cap medical�technology and systems�stock CareFusion Corporation (NYSE: CFN) could offer nice growth in the healthcare space, meaning its worth taking a closer look at the stock along with the performance of potential benchmarks like the iShares Dow Jones US Medical Device ETF (NYSEARCA: IHI) and SPDR S&P Health Care Equipment ETF (NYSEARCA: XHE). I should mention that we have recently added CareFusion Corporation to our SmallCap Network Elite Opportunity (SCN EO) portfolio because the�stock continues to be in a long-term thrusting patter and we believe its also�undervalued based on current valuation.
- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on CareFusion (NYSE: CFN ) , whose recent revenue and earnings are plotted below.
Hot Asian Stocks To Invest In 2014: Iron Mountain Incorporated(IRM)
Iron Mountain Incorporated, together with its subsidiaries, provides information management services primarily in North America, Europe, Latin America, and the Asia Pacific. The company offers records management services, including records management program development and implementation based on best-practices to help customers comply with specific regulatory requirements; implementation of policy-based programs that feature storage for various media comprising paper; flexible retrieval access and retention management; hybrid services to help organizations gain control over their paper records; and specialized services for vital records and regulated industries, such as healthcare, energy, government, and financial services. It also provides data protection and recovery services, such as disaster preparedness; off-site vaulting of data backup media for data recovery in the event of a disaster, human error, or virus; online backup and recovery solutions for desktop and la ptop computers, and remote servers; and technology escrow services to protect and manage source code and other proprietary information. In addition, the company offers information destruction services that primarily consist of physical secure shredding operations; and is involved in the shredding of sensitive documents to third-party recyclers. Further, it provides fulfillment services that assemble custom marketing packages and orders, as well as provide reporting on customer marketing literature inventories; and professional consulting services to develop and implement comprehensive records and information management programs. Iron Mountain Incorporated serves commercial, legal, banking, health care, accounting, insurance, entertainment, and government organizations. The company was founded in 1951 and is headquartered in Boston, Massachusetts.
Advisors' Opinion:- [By Sally Jones] 12% over 12 months, Iron Mountain Inc. has a market cap of 5.46 billion; its shares were traded at around $28.56 with a P/E ratio of 69.70. The dividend yield is 3.78%.
The company reported financial results for the third quarter of 2013 with revenue of $756 million, up from $748 million in the same quarter of 2012. Iron Mountain reported adjusted OIBDA at $240 million in the third quarter, down from the prior-year quarter at $244 million. The third quarter 2013 adjusted EPS of $0.03 per share (GAAP) was also down from the year-ago quarter at $0.31 (GAAP). Year-to-date revenue is $2.25 billion, up slightly from $2.24 billion in third quarter of 2012.
In October, Iron Mountain bought Cornerstone Records Management, another records storage and data protection company for $191 million. According to a company press release, the Cornerstone deal follows other recent acquisitions of similar companies in Colombia and Peru. Iron Mountain has completed acquisitions valued at approximately $320 million in 2013. The company is also utilizing Paragon Solutions, an advisory consulting and systems integration firm, to be able to advise clients about managing their electronic records.
GuruFocus currently ranks Iron Mountain with 3 out of 5 stars for Business Predictability.
Iron Mountain has a real estate network of 64 million square feet across nearly 1,000 facilities in 36 countries. The company operates in five segments: North American Physical Business, Worldwide Digital Business, Europe, Latin America and Asia Pacific.
Track share pricing, revenue and net income:
[ Enlarge Image ]
Real Time Guru Action: As of Nov. 18, 2013, Chris Davis reduced his IRM position by 1.91%, selling 72,606 shares at an average price of $27.48 per share, gaining 3.9%.
This trade follows his third quarter reduction as of Sept. 30, 2013, when Chris Davis reduced his position by 51.23%, selling 6,628,314 shares at an average price of $64.10, for a g
Hot Asian Stocks To Invest In 2014: Idera Pharmaceuticals Inc.(IDRA)
Idera Pharmaceuticals, Inc., a biotechnology company, discovers and develops DNA- and RNA-based drug candidates for the treatment of infectious diseases, autoimmune and inflammatory diseases, cancer, and asthma and allergies, and for use as vaccine adjuvants. The company designs and creates proprietary Toll-Like Receptors (TLR) to modulate immune responses, including TLR agonist, a compound that stimulates an immune response through the targeted TLR; and TLR antagonist, a compound that blocks activation of an immune response through the targeted TLR. Its drug candidates include IMO-2125, a TLR9 agonist, which is in Phase 1 clinical trial for hepatitis C virus infection; and TLR7, 8, and 9 agonists that are in research stage for viral diseases. The company also develops IMO-3100, a dual TLR7/TLR9 antagonist, which is in preclinical development stage for autoimmune and inflammatory diseases, such as lupus, rheumatoid arthritis, multiple sclerosis, psoriasis, and colitis. In addition, its drug candidates also comprise TLR7 and TLR8 agonists that are in research stage for solid tumor cancers. The company has a licensing and collaboration agreement with Merck KGaA to research, develop, and commercialize TLR9 agonists for the treatment of cancer, excluding cancer vaccines; a license and research collaboration agreement with Merck & Co., Inc. to research, develop, and commercialize therapeutic and prophylactic vaccine products containing its TLR7, 8, and 9 agonists in the fields of cancer, infectious diseases, and Alzheimer?s disease; and a research collaboration and option agreement, and a license, development, and commercialization agreement with Novartis International Pharmaceutical, Ltd. to discover, develop, and commercialize TLR9 agonists for the treatment of asthma and allergies. The company was founded in 1989 and is based in Cambridge, Massachusetts.
Advisors' Opinion:- [By Jake L'Ecuyer]
Leading and Lagging Sectors
In trading on Tuesday, healthcare shares were relative leaders, up on the day by about 1.50 percent. Meanwhile, top gainers in the sector included Allergan (NYSE: AGN), up 15.7 percent, and Idera Pharmaceuticals (NASDAQ: IDRA), up 16.5 percent. Non-cyclical consumer goods & services shares dropped around 0.05 percent in today's trading.
Hot Asian Stocks To Invest In 2014: Internet Initiative Japan Inc.(IIJI)
Internet Initiative Japan Inc., together with its subsidiaries, provides Internet connectivity, WAN, outsourcing, and systems integration services to customers primarily in Japan. Its Internet connectivity services include services for corporate use, such as IP services and data center connectivity services, broadband Internet connectivity services, dial-up access services, IIJ mobile services, and IIJ ISDN/F and IIJ line management/F services; and connectivity services for home use consisting of IIJ4U, IIJmio, and hi-ho. The company?s outsourcing services comprise security-related outsourcing services that protect customer network systems from unauthorized access and secure remote connections to internal networks; network-related outsourcing services, such as Internet-virtual private network, and router rental; server-related outsourcing services, including Web hosting, e-mail hosting, document storage, and streaming; data center-related outsourcing services consisting o f data center facility, and management and monitoring; and customer support and help desk solutions, and IP phone services. It also provides systems integration services, which include consulting, project planning, systems design, and development of network systems, primarily focusing on Internet business systems, and Intranet and Extranet corporate information systems; and systems operation and maintenance services. In addition, the company sells network-related equipment, as well as provides automated teller machine (ATM) services. As of June 30, 2011, it operated 9 points of presence (POPs) for dedicated access and 1 POP for nationwide dial-up access. The company also operates approximately 280 ATMs and 16 Internet data centers. Internet Initiative Japan Inc. was founded in 1992 and is headquartered in Tokyo, Japan.
Advisors' Opinion:- [By Jake L'Ecuyer]
Leading and Lagging Sectors
Thursday morning, the telecommunications services sector proved to be a source of strength for the market. Leading the sector was strength from ARC Group Worldwide (NASDAQ: ARCW) and Internet Initiative Japan (NASDAQ: IIJI). In trading on Thursday, non-cyclical consumer goods & services shares were relative laggards, down on the day by about 0.43 percent. - [By Jake L'Ecuyer]
Telecommunications services sector was the leading decliner in the US market today. Top decliners in the sector included Internet Initiative Japan (NASDAQ: IIJI), off 3.7 percent, and BT Group plc (NYSE: BT), down around 2.7 percent.
- [By Jake L'Ecuyer]
Leading and Lagging Sectors
In trading on Thursday, telecommunications services shares were relative leaders, up on the day by about 0.83 percent. Top gainers in the sector included Internet Initiative Japan (NASDAQ: IIJI), with shares up 9.5 percent, and RRSat Global Communications Network (NASDAQ: RRST), with shares up 4.9 percent.
Hot Asian Stocks To Invest In 2014: Spectrum Pharmaceuticals Inc.(SPPI)
Spectrum Pharmaceuticals, Inc., a commercial-stage biotechnology company, primarily focuses on oncology and hematology. The company engages in acquiring, developing, and commercializing a broad and diverse pipeline of late-stage clinical and commercial products. It markets Zevalin, a prescribed form of cancer therapy, radioimmunotherapy; and Fusilev, a novel folate analog formulation and the pharmacologically active isomer of the racemic compound, calcium leucovorin. The company?s drugs in late stage development include Apaziquone, an anti-cancer agent; and Belinostat, a histone deacytelase inhibitor. Its drugs in development also include Ozarelix a luteinizing hormone releasing hormone antagonist, which is in Phase II clinical stage; SPI-1620, a peptide agonist of endothelin B receptors, which is in Phase I clinical stage; and RenaZorb, a lanthanum-based nanoparticle phosphate binding agent, which is in preclinical stage. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Henderson, Nevada.
Advisors' Opinion:- [By Roberto Pedone]
Another under-$10 biotechnology player that's starting to move within range of triggering a near-term breakout trade is Spectrum Pharmaceuticals (SPPI) which develops and commercializes oncology and hematology drug products. This stock has traded off a bit so far in 2014, with shares off by 7.3%.
If you take a glance at the chart for Spectrum Pharmaceuticals, you'll see that this stock has been uptrending over the last month and change, with shares moving higher from its low of $6.75 to its recent high of $8.50 a share. During that uptrend, shares of SPPI have been making mostly higher lows and higher highs, which is bullish technical price action. This move has now pushed shares of SPPI within range of triggering a near-term breakout trade above some key overhead resistance levels.
Traders should now look for long-biased trades in SPPI if it manages to break out above some near-term overhead resistance levels at $8.25 to $8.50 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 1.07 million shares. If that breakout gets underway soon, then SPPI will set up to re-test or possibly take out its next major overhead resistance levels at $9.27 to its 52-week high at $10.32 a share. Any high-volume move above $10.32 will then give SPPI a chance to re-fill some of its previous gap-down-day zone from March of 2013 that started at $12.47 a share.
Traders can look to buy SPPI off weakness to anticipate that breakout and simply use a stop that sits right below its recent double bottom support levels at $7.82 to $7.81 a share or right below its 50-day moving average of $7.69 a share. One can also buy SPPI off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Read More: 5 Hated Earnings Stocks You Should Love
- [By Rich Smith]
Spectrum Pharmaceuticals (NASDAQ: SPPI ) has found itself a new Executive Vice President, a new Chief Financial Officer, and a new Principal Accounting�Officer. They're all the same person.
- [By Jake L'Ecuyer]
Spectrum Pharmaceuticals (NASDAQ: SPPI) shares tumbled 9.77 percent to $8.18 after the company announced an offering of $100 million of convertible notes.
Hot Asian Stocks To Invest In 2014: Nestle SA (NESN)
Nestle SA is a Swiss Company engaged in the nutrition, health and wellness sectors. It is the holding company of the Nestle Group, which comprises subsidiaries, associated companies and joint ventures throughout the world. It has such business units as Food and Beverage, Nestle Waters and Nestle Nutrition. It is also active in the pharmaceutical sector. It divides its products into Powdered and liquid beverages, Water, Milk products and Ice cream, Nutrition, Prepared dishes and cooking aids, Confectionery, PetCare and Pharmaceutical products. In February 2011, the Company acquired CM&D Pharma Ltd. Advisors' Opinion:- [By Chad Fraser]
These are the first significant moves made by the Caira, a former executive at Nestle SA (NYSE: NESN) who helped expand that company’s hot and cold beverage division.
- [By Corinne Gretler]
Swiss stocks fell for a second day, their first back-to-back losses this month, as Nestle (NESN) SA retreated after reporting slower growth in sales.
- [By Celeste Perri]
Nestle SA (NESN) is selling Givaudan (GIVN) SA shares worth $1.27 billion at yesterday�� closing price to institutional investors, winding down its stake in the world�� largest flavorings maker.
Hot Asian Stocks To Invest In 2014: BioAmber Inc (BIOA)
BioAmber Inc. (BioAmber), incorporated on October 15, 2008, is a chemical company. The Company manufactures its bio-succinic acid in a facility using a commercial scale 350,000 liter fermenter in Pomacle, France. During the year ended December 31, 2011, the Company produced 487,000 pounds, or 221 metric tons, of bio-succinic acid at this facility. Succinic acid is used to manufacture a range of products used every day, including plastics, food additives and personal care products, and can also be used as a building block for a range of derivative chemicals. The Company produces and sells bio-succinic acid using its process for petroleum-derived succinic acid. It also has additional bio-based products under development with partners including bio-succinic acid derivatives, such as BDO, and applications of bio-succinic acid, such as plasticizers, polyurethanes and de-icing solutions. During 2011, the Company created a wholly owned subsidiary, BioAmber International, S.a.r.l.
The Company develops bio-succinic acid for a range of markets, such as personal care products and food additives, plasticizers, polyurethanes, resins and coatings. The applications for bio-succinic acid include plasticizers, polyurethanes, personal care products, de-icing solutions, resins and coatings, food additives, lubricants and other products. Plasticizers are organic esters that are primarily used to make flexible polyvinyl chloride. Adipic acid is used in polyester polyols, which are used to make polyurethanes. Polyurethanes are used in, among other things, soles for footwear, molded foams for automotive applications, such as car seats and arm rests, and non-foam applications such as coatings, adhesives and sealants. Other applications of bio-succinic acid that are developed and tested by potential customers, which include anti-freeze solutions, solvents, water treatment chemicals and effervescence agents such laundry tablets and bath salts.
The Company competes with Gadiv Petrochemical Industries ! Ltd., Mitsubishi Chemical, DSM, Anqing Hexing Chemical Co Ltd, Anhui Sunsing Chemicals Co., Ltd., Genomatica, Inc., Myriant Corporation and Roquette Freres S.A.
Advisors' Opinion:- [By Markus Aarnio]
BioAmber (BIOA) is a sustainable chemicals company. Its proprietary technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstock into chemicals for use in a wide variety of everyday products including plastics, resins, food additives and personal care products.
- [By Maxx Chatsko]
He believes several companies have set the bar precipitously low to start the year despite targeted developments expected to occur before the start of 2014. Watch the following video for his thoughts on potential positive surprises awaiting investors in�Amyris� (NASDAQ: AMRS ) ,�BioAmber� (NYSE: BIOA ) ,�Codexis� (NASDAQ: CDXS ) , and�Solazyme� (NASDAQ: SZYM ) .
No comments:
Post a Comment